^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials
Published date:
11/01/2018
Excerpt:
In CRY-04 study, patients were treated with six courses of R-CHOEP14 followed by HD-Mtx and HD-Ara-C...when treatment interaction was tested, MYC/BCL2 double hit status (DHL; 13%) predicted poor outcome among patients treated with CRY-04 regimen compared with patients who received CHIC regimen (4-y PFS; 38% vs 78%, p=0.086).
Secondary therapy:
EPOCH-R
DOI:
10.1182/blood-2018-99-120057
